Ligand Pharmaceuticals | LGND - Zinsaufwendungen Für Schuld

Aktienkurs
204.81
Täglich Wechseln
-5.68 -2.70%
Monatlich
11.52%
Jährlich
89.38%
Q1 Prognose
198.67




Zinsaufwendungen Für Schuld Veränderung Datum
Agenus USD 16.02M 2.85M 2025-12
Amgen USD 653M 32M 2025-12
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
Baxter International USD 58M 14M 2025-09
Bristol-Myers Squibb USD 432M 48M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Enviri Corporation USD 28.44M 1.74M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.6M 217K 2025-12
Intrexon USD 2K 5K 2024-06
Ionis Pharmaceuticals USD 18M 0 2025-12
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
Ligand Pharmaceuticals USD 910K 243K 2025-09
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 412M 85M 2025-12
Pacira USD 3.89M 387K 2025-12
Pfizer USD 711M 59M 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Veracyte USD 2K 1000 2023-12